AHA video: Critics take high aim at AIM-HIGH; Boden responds
William E. Boden, MD, principal investigator of AIM-HIGH, spoke with Cardiovascular Business about the findings of his 2011 AHA late-breaking clinical trial. Source: University of Buffalo |
In May, the National Heart, Lung and Blood Institute stopped AIM-HIGH (co-sponsored by Abbott Laboratories), which was studying a blood lipid treatment, 18 months earlier than planned. However, Boden parsed out some of that discontinuation, including that the physicians involved learned about the trial's cessation a day after the decision. He also explained use of niacin in his clinical practice.
This video was conducted collaboratively with ClinicalTrialResults.org.